Free Trial

Victory Capital Management Inc. Purchases 69,531 Shares of The Chemours Company (NYSE:CC)

Chemours logo with Basic Materials background

Victory Capital Management Inc. raised its position in shares of The Chemours Company (NYSE:CC - Free Report) by 206.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 103,259 shares of the specialty chemicals company's stock after acquiring an additional 69,531 shares during the quarter. Victory Capital Management Inc. owned approximately 0.07% of Chemours worth $2,098,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Marshall Wace LLP boosted its position in shares of Chemours by 23.8% in the 2nd quarter. Marshall Wace LLP now owns 7,009,868 shares of the specialty chemicals company's stock worth $158,213,000 after purchasing an additional 1,347,710 shares in the last quarter. Khrom Capital Management LLC raised its stake in Chemours by 54.6% during the second quarter. Khrom Capital Management LLC now owns 3,456,626 shares of the specialty chemicals company's stock valued at $78,016,000 after buying an additional 1,220,967 shares during the last quarter. Forest Avenue Capital Management LP boosted its holdings in Chemours by 236.9% in the second quarter. Forest Avenue Capital Management LP now owns 845,728 shares of the specialty chemicals company's stock worth $19,088,000 after acquiring an additional 594,660 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Chemours by 26.7% in the second quarter. American Century Companies Inc. now owns 1,811,957 shares of the specialty chemicals company's stock worth $40,896,000 after acquiring an additional 382,100 shares during the last quarter. Finally, Private Management Group Inc. increased its holdings in shares of Chemours by 72.0% during the third quarter. Private Management Group Inc. now owns 785,809 shares of the specialty chemicals company's stock valued at $15,968,000 after acquiring an additional 329,037 shares in the last quarter. 76.26% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. JPMorgan Chase & Co. dropped their price target on shares of Chemours from $25.00 to $18.00 and set a "neutral" rating on the stock in a research note on Tuesday, August 6th. BMO Capital Markets increased their price target on shares of Chemours from $30.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, October 7th. Barclays boosted their target price on Chemours from $21.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Tuesday, November 5th. Royal Bank of Canada reduced their price target on shares of Chemours from $28.00 to $25.00 and set an "outperform" rating for the company in a research note on Wednesday, November 6th. Finally, UBS Group lowered their price target on Chemours from $30.00 to $28.00 and set a "buy" rating on the stock in a report on Tuesday, August 6th. Five investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Chemours currently has an average rating of "Hold" and an average price target of $24.88.

View Our Latest Research Report on CC

Insider Buying and Selling

In other Chemours news, SVP Alvenia Scarborough sold 7,500 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $20.64, for a total transaction of $154,800.00. Following the completion of the sale, the senior vice president now directly owns 16,645 shares of the company's stock, valued at $343,552.80. This trade represents a 31.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.47% of the stock is currently owned by insiders.

Chemours Stock Performance

Shares of NYSE:CC traded up $0.47 during midday trading on Monday, hitting $22.00. The company had a trading volume of 444,691 shares, compared to its average volume of 1,573,118. The company has a market cap of $3.29 billion, a price-to-earnings ratio of 43.20 and a beta of 1.75. The company has a debt-to-equity ratio of 6.05, a current ratio of 1.73 and a quick ratio of 0.92. The company has a fifty day moving average of $19.39 and a two-hundred day moving average of $21.48. The Chemours Company has a 12-month low of $15.10 and a 12-month high of $32.70.

Chemours (NYSE:CC - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share for the quarter, beating analysts' consensus estimates of $0.32 by $0.08. The firm had revenue of $1.50 billion for the quarter, compared to analysts' expectations of $1.44 billion. Chemours had a return on equity of 29.48% and a net margin of 1.34%. The business's quarterly revenue was up .9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.64 EPS. On average, equities research analysts expect that The Chemours Company will post 1.35 EPS for the current fiscal year.

Chemours Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Friday, November 15th will be paid a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 4.55%. The ex-dividend date of this dividend is Friday, November 15th. Chemours's dividend payout ratio (DPR) is 200.00%.

About Chemours

(Free Report)

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

See Also

Institutional Ownership by Quarter for Chemours (NYSE:CC)

Should you invest $1,000 in Chemours right now?

Before you consider Chemours, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chemours wasn't on the list.

While Chemours currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Best ETFs for 2025: Growth, Stability, and AI-Driven Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines